Surmodics, Inc. (SRDX)

Market Cap	431.98M
Revenue (ttm)	121.58M
Net Income (ttm)	-19.86M
Shares Out	14.30M
EPS (ttm)	-1.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,544
Open	30.85
Previous Close	30.62
Day's Range	30.00 - 31.53
52-Week Range	26.00 - 41.98
Beta	1.31
Analysts	Buy
Price Target	43.00 (+42.34%)
Earnings Date	Jul 30, 2025

About SRDX

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 4, 1998
• Employees: 389
• Stock Exchange: NASDAQ
• Ticker Symbol: SRDX
• Website: https://www.surmodics.com

Financial Performance

In 2024, Surmodics's revenue was $126.08 million, a decrease of -4.91% compared to the previous year's $132.58 million. Losses were -$11.54 million, 651.4% more than in 2023.

Analyst Summary

According to 2 analysts, the average rating for SRDX stock is "Buy." The 12-month stock price target is $43.0, which is an increase of 42.34% from the latest price.

Price Target

$43.0

(42.34% upside)

Analyst Consensus: Buy